About Checkpoint Therapeutics (CKPT)

Checkpoint Therapeutics Inc is a biopharmaceutical company that focuses on the development and commercialization of immune-enhanced combination therapies for the treatment of cancer. The company's lead product candidate, CK-101, is an inhibitor of the epidermal growth factor receptor (EGFR), which is being evaluated in a Phase 1/2 clinical trial in patients with advanced non-small cell lung cancer (NSCLC). CK-101 has demonstrated promising activity in preclinical models, and the ongoing clinical trial aims to assess its safety and efficacy in NSCLC patients. In addition to CK-101, Checkpoint Therapeutics is also developing CK-301, an anti-programmed death ligand 1 (PD-L1) antibody, as a potential treatment for multiple cancers. CK-301 is currently being evaluated in a Phase 1 clinical trial in patients with selected solid tumors.

The market cap of Checkpoint Therapeutics Inc is currently __MARKET_CAP___. The company's stock, CKPT, has experienced fluctuations over the past year, with a 52-week range of __52_WEEK_RANGE__. As of the latest trading session, the stock had a day range of __DAY_RANGE__ and a trading volume of __TRADING_VOLUME___. It is important to note that the stock price history of Checkpoint Therapeutics Inc can be influenced by various factors, including clinical trial results, regulatory approvals, and market trends. Investors should carefully consider these factors before making any investment decisions.